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Abstract
The biological role of the protein encoded by the alternative open reading frame (core+1/ARF) of the Hepatitis C virus (HCV)
genome remains elusive, as does the significance of the production of corresponding antibodies in HCV infection. We
investigated the prevalence of anti-core and anti-core+1/ARFP antibodies in HCV-positive blood donors from Cambodia,
using peptide and recombinant protein-based ELISAs. We detected unusual serological profiles in 3 out of 58 HCV positive
plasma of genotype 1a. These patients were negative for anti-core antibodies by commercial and peptide-based assays
using C-terminal fragments of core but reacted by Western Blot with full-length core protein. All three patients had high
levels of anti-core+1/ARFP antibodies. Cloning of the cDNA that corresponds to the core-coding region from these sera
resulted in the expression of both core and core+1/ARFP in mammalian cells. The core protein exhibited high amino-acid
homology with a consensus HCV1a sequence. However, 10 identical synonymous mutations were found, and 7 were
located in the aa(99–124) region of core. All mutations concerned the third base of a codon, and 5/10 represented a T.C
mutation. Prediction analyses of the RNA secondary structure revealed conformational changes within the stem-loop region
that contains the core+1/ARFP internal AUG initiator at position 85/87. Using the luciferase tagging approach, we showed
that core+1/ARFP expression is more efficient from such a sequence than from the prototype HCV1a RNA. We provide
additional evidence of the existence of core+1/ARFP in vivo and new data concerning expression of HCV core protein. We
show that HCV patients who do not produce normal anti-core antibodies have unusually high levels of antit-core+1/ARFP
and harbour several identical synonymous mutations in the core and core+1/ARFP coding region that result in major
changes in predicted RNA structure. Such HCV variants may favour core+1/ARFP production during HCV infection.
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Introduction
Hepatitis C virus (HCV) infection is a major cause of chronic
liver disease worldwide, which can evolve to hepatic steatosis,
cirrhosis and hepatocellular carcinoma [1]. HCV is an enveloped
virus of the Flaviviridae family with a single-stranded positive sense
RNA genome of about 9.6 kb. The viral genome is composed of a
59non-coding region (UTR), one ORF encoding the precursor
protein of about 3000 amino-acids, and a 39UTR. The polypro-
tein is cleaved by host and viral proteases into the core protein,
envelope glycoproteins E1 and E2, P7, and several non-structural
proteins that have various functions in RNA replication and virus
morphogenesis [2].
Bioinformatic analyses of the HCV RNA fragment that encodes
the virus nucleocapsid protein provided evidence that this
sequence is highly conserved and has a particularly complex
structure, suggesting that it has multiple functions. Indeed, as for
other human viruses such as HIV or HBV, HCV has an
alternative open reading frame (ARF) that overlaps with a second
gene, in this case that encoding core [3]. Experimental data
confirmed that the HCV ARF can be expressed in cell-free
systems [4,5] and in mammalian cells [6,7,8]. The biological
properties of this protein (known as ARFP, F or core+1 protein,
but that will be referred here to as core+1/ARFP), its role in the
HCV life-cycle and pathogenesis of infection remain elusive. The
core+1/ARFP has not yet been detected either in patient sera or in
infected tissues. However, unusual translation events resulting in
core+1/ARFP production most probably do take place in natural
HCV infection, as core+1/ARFP-specific humoral and T-cell
responses have been detected in HCV-infected individuals [3,4,9,
10,11,12,13,14,15].
Core+1/ARFP production could be initiated by one of several
molecular mechanisms in cultured cells: (i) a ribosomal frameshift
promoted by a cluster of 10 adenines at codons 8–11 of HCV
RNA, which could induce either +1 or –1 programmed frameshift
(limited to the genotype 1 genome), [4,5,7,16]; (ii) a double
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ribosomal frameshift, with the first event occurring at codon 42 (in
phase +1) and the second event at codon 144 (in phase -1), which
enables ‘‘reframing’’ of translation and production of the ‘‘doubly
frameshifted core protein’’ for genotype 1b HCV [17]; (iii)
‘‘transcriptional slippage’’ within the region of the 10 consecutive
adenines at codons 8–11 of HCV-1 strains [18]; (iv) an internal
translation initiation mechanism at codons 85–87[8] or codon 26
[6]. Notably, ribosomal or transcriptional slippage occurs in
genotype 1a HCV only when 10 consecutive adenines are present
in the core region, in codons 8–11[19].
Core+1/ARFP expressed in vitro is rather unstable and is readily
degraded by the proteasome complex [5,7,20,21]. Nevertheless, a
perinuclear distribution of core+1/ARFP could be observed in
transfected cells [7,20]. Core+1/ARFP does not appear to play a role
in virus replication vitro [22]. In addition, point mutations within the
JFH-1 core+1/ARFP ORF or chimeric H77/JFH-1 strains do not
affect virus production [16,23]. However, the basic nature of core+1/
ARFP, and the fact that it localises to the cell cytoplasm, suggests the
possibility that it interacts with the HCV RNA [24].
The HCV core protein influences lipoprotein metabolism, cell
transformation, regulation of cellular genes, transcriptional
mechanisms, apoptosis, and cellular immune responses [25,26].
It is conceivable that core+1/ARFP could be responsible for some
of these biological functions attributed up to now to core. Indeed,
the induction of fibrogenic chemokines [27], suppression of
cellular p21 [28], perturbation of the microtubule network [29],
activation of the intracellular NF-kB pathway[30] and enhance-
ment of c-myc activity [14] have all recently been attributed to
core+1/ARFP. These findings suggest that core+1/ARFP could
play a role in HCV pathogenesis.
In this study, high levels of anti-core+1/ARFP antibodies were
found in three patients from Cambodia, who had no antibodies
directed against the core protein detectable by routine and home-
made assays. This unusual serological profile could be linked to
several synonymous mutations in the core and core+1/ARFP coding
region that result in major changes in predicted RNA structure, and
that may favour core+1/ARFP production. Our study provides
further evidence for the production of core+1/ARFP in natural HCV
infection and new information concerning the expression of the core
protein, which is thought to play a major role in HCV pathogenesis.
Materials and Methods
Plasma samples
A panel of 87 plasma samples were from volunteer blood donors
residing in Cambodia. All samples were collected between
November 2002 and June 2003 by the National Blood Transfusion
Centers (NBTC) in Phnom Penh and Battambang, in the
Kingdom of Cambodia. Blood donations were from voluntary
donors that included patient family members (‘‘replacement
donors’’), unpaid volunteer donors from NBTC (‘‘spontaneous
donors’’), and samples collected through mobile blood campaigns
(‘‘external donors’’). All plasma samples were screened by NBTC
for various serological markers and selected samples were coded
before reaching the Virology Unit of the Pasteur Institute of
Cambodia, where they were processed.
The panel included 87 plasma samples: 58 HCV positive
plasma were selected by the NBTC among other samples found
positive by routine diagnostic assays and completed with 29 HCV
negative plasma collected from the same region.
Ethics Statement
All plasma samples used in this study were from volunteer blood
donors. Scientific agreement has been signed between the Pasteur
Institute of Cambodia and NBTS concerning the improvement of
HCV diagnostics. All samples were coded before reaching the
Virology Unit of the Pasteur Institute of Cambodia, and thus
treated anonymously. The protocol for the study has been
submitted to the National Ethics Committee for Health Research
at Ministry of Health of the Kingdom of Cambodia in September
2002 by the Pasteur Institute of Cambodia. Authorisation was
granted by the National Ethics Committee for Health Research
and agreement delivered by the Ministry of Health of the
Kingdom of Cambodia in October 2002 (Document signed under
No 1296/02 OGH).
Serological analyses
Of 87 above mentioned plasma samples, 58 were found to be
positive for anti-HCV antibodies using 3 assays: 1) SerodiaH HCV
(Fujirebio, Japan), 2) Monolisa anti-HCV PLUS Assay Version 2
(BioRad, Marne la Coquette, France), 3) a third generation
microparticle enzyme immunoassay (MEIA) (AxSYM HCV, version
3.0; Abbott, Wiesbaden, Germany). Anti-HCV antibodies were also
measured using a Chiron RIBA HCV 3.0 Strip Immunoblot Assay
(SIA) (Ortho Clinical Diagnostics Illkrich, France).
HCV RNA was determined by PCR in the 59 non-coding
region (UTR). After reverse transcription, nested PCR targeting
the 59UTR was performed as previously described [31,32]. The
virus load in selected sera was measured by the b-DNA assay
(Versant HCV RNA 3.0, Simmens Health Care Diagnostics St.
Denis, France). HCV core antigen was assessed by commercial
ELISA assay (Ortho Diagnostics, Wako, Germany).
HCV genotyping
HCVNS5B region sequences in RNA isolated from plasma were
amplified by nested RT-PCR [33]. cDNAs were obtained by
reverse transcription in a 20 ml reaction mixture containing: 300 ng
of random primer (hexanucleotide Pd(N)6, Roche), 10 ml RNA,
0.4x RT buffer (Promega), 0.5 mM dNTP, 24 U RNAsin
(Promega), 8 U AMV RT (Promega). The 59-TAT GAY ACC
MGV TGY TTT GAM TC-39 and 59-GCN GAR TAY CTV
GTC ATR GCY TC-39 primers were used to amplify a 388 bp
NS5B PCR product. The second round PCR primers: 59-CGC
TGYTTTGAMTCVACNGTCAC-39 and 59-CTVGTC ATR
GCY TCY GTR AAV CTC-39 were used to amplify a 371 bp
NS5B nested-PCR product. The 50 ml reaction mixture for the first
PCR step contained 5 ml cDNA, each primer at 0.4 mM, 1.5 mM
MgCl2, 0.2 mM dNTP and 1.5 U Tag DNA polymerase, the
whole in 1x Tag DNA polymerase buffer. Nested-PCR, primed
with 2 ml of PCR product, was performed as for the first PCR run.
The NS5B-derived sequences were analysed and compared to
reference sequences with the Phylip sequence analysis package
(version 3.6 alpha 3) using DNAdist with Kimura’s correction,
followed by the neighbour-joining method [33].
Construction of plasmids
Cloning was performed according to standard protocols
(Maniatis), and all plasmid constructions were confirmed by
DNA sequencing. cDNA fragments between nucleotides 1-873
that contain the core/core+1 coding sequences from the HCV1a
H strain or from the Cambodian clinical isolate number 34
(HCV1a p34) were amplified from pHPI-1397 [33,34] and the
TOPO-based plasmid MR0582-1, using 59-CTAGCTAGCATGA-
GCACAAATCCTAA-39 (sense) and 59-GCTCTAGATCAG-
GCTGAAGCGGGC-39 (antisense) primers (here, and in follow-
ing primers, restriction sites are shown in italics, and initiator ATG
and termination codons are in bold) and were blunt-end ligated
into the HincII site of pUC19 to yield pHPI-8153 and pHPI-8156,
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respectively. To express the core-coding region in eukaryotic cells,
the NheI-XbaI fragment from these plasmids was cloned into the
pCI eukaryotic expression vector to yield pHPI-8161 (HCV1a H)
and pHPI-8162 (HCV1a p34).
For the synthesis of recombinant genotype 1a core protein in
E.coli, a cDNA fragment between nt 1 and 360 was amplified from
pHPI-1319[34] using 5-GGAATTCCATATGAGCACGAAT-3
(HCV1a sense) and 59-CCCAAGCTTACCCAAATTGCG-39
(antisense) primers, and blunt-end ligated into the HincII site of
pUC19 to yield pHPI-8128. Next, the NdeI-HindIII fragment from
pHPI-8128 was cloned into the pET20b (+) expression vector,
upstream of the hexahistidine tail, to generate plasmids pHPI-
8130. To express the HCV1a core+1/ARFP coding region in
E.coli, a cDNA fragment between nt 44 and 487 was amplified
using 59-CATGCCATGGCATGGCCAACCGTCGCCCACA-
39 (sense) and 59-CCCAAG CTTGGGTCCCGCCGTCTTCC-
AGAACCCGGA-39 (antisense) primers, and the NcoI–HindIII
digested PCR product was cloned into the pET20b(+) expression
vector.
To construct the IRES-ARF-LUC expression cassette, a cDNA
fragment from HCV nt 1 to 484 was amplified from pHPI-8162
(HCV1a p34) or pHPI-8161 (HCV1a H) using 59-CGGATCCAT-
GAGCACGAATCCTAAACC-39 (sense) and 59-CGGATCCTC-
GCCGTCCTCCAGAACCCGGAC-39 (antisense) primers, and
cloned into the SmaI site of pUC19, to give pHPI-8217 and pHPI-
8221. Next, the BamHI-BamHI fragment from these plasmids was
cloned directly into pGEM-luc (Promega), in frame with the
luciferase gene, to yield plasmids pHPI-8224 (HCV1a p34 ARF-
LUC) or pHPI-8223 (HCV1a H strain ARF-LUC). Finally, the
XhoI-XhoI fragments of these plasmids were replaced into pHPI-
1808 (kindly provided by M. Kochlios; based on the pEGFP N3
expression vector, that contains the C-terminal ARFP sequence
fused to GFP) to construct pHPI-8227 and pHPI-8235 that
contain the IRES-ARF-LUC sequences inserted into eukaryotic
expression vector. Plasmid pHPI-8234 was also constructed, which
contains the XhoI fragment of HCV1a (H strain) in the reverse
orientation.
Amplification, cloning and sequencing of the HCV core
gene
Total RNA extracted from the plasma of 8 patients infected
with genotype 1a HCV (5 with normal anti-core responses and 3
who were negative for anti-core and highly positive for anti-
core+1/ARFP) was reverse transcribed. Then, the full-length core
gene was amplified by PCR using 59CTTGTGGTATGCCT-
GATA39 and 59ACGATGCTGGWGTTRGGGCA39 primers,
followed by nested PCR with 59-GAGGTCTCGTAGACCGT-
GCA-39 and 59GGCAATCATTKGTRAGATGGTA39 primers.
The PCR products were cloned into a plasmid (Topo TA
cloning, Invitrogen) and sequenced in triplicate. Nucleotide
and protein sequences were aligned using the CLUSTAL W
program. Predicted analyses of RNA secondary structures in the
core and core+1/ARFP coding regions were performed using the
mfold program (version 3.2). http://frontend.bioinfo.rpi.edu/
applications/mfold/cgi-bin/rna-form1.cgi.
Expression and purification of the HCV core and core+1/
ARF Proteins
Expression and purification of the histidine-tagged HCV core+1/
ARFP and core protein aa(1-120) was carried out as previously
described [34,35]. It is important to note that the recombinant
core+1/ARFP antigen deliberately does not contain amino acids
from the N-terminal part of the core protein. Furthermore, tagging
the core+1/ARF at the C-terminal end appears to minimize the
possibility that mosaic core/core+1/ARFP proteins are obtained
due to the frameshifting events that are favoured in E.coli
(N.Vassilaki and P.Mavromara unpublished data). The size and
identity of the recombinant proteins were controlled by Western
blot analysis using anti-core+1/ARFP and anti-core antibodies.
Detection of anti-core and anti core+1/ARFP antibodies
by ELISA
Antibodies to HCV core protein were detected using a synthetic
core peptide aa(3–75) of genotype 1a and recombinant core
Figure 1. Schematic representation of the fragments of HCV core and core+1/ARF proteins used in ELISA for detection of anti-core
and anti-core+1/ARFP antibodies. Core aa(1–120) and core+1/ARF aa(14–160) recombinant proteins were expressed in E.coli from the pET20T
vector. Synthetic core aa(3–75) and core+1/ARF aa(91–106) peptides are shown. Details concerning the synthesis and purification of antigens are
described in the Material and Methods section.
doi:10.1371/journal.pone.0015871.g001
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protein aa(1–120). The assay conditions were set-up using a
reference panel of human sera, which included 10 HCV-positive,
10 HBV-positive samples, and 10 plasma from healthy controls.
Antibodies directed against core+1/ARFP were detected using
a recombinant 1a protein. Rabbit anti-ARFP antibodies [20] and
5 serum samples from HCV-infected patients that were positive for
anti-core+1/ARFP and rabbit anti-core+1/ARFP antibody were
used as positive controls. The specificity of the assay was
confirmed using anti-core+1/ARFP positive samples kindly
provided by J.M Pawlotsky.
The antigens were used at a concentration of 1–5 mg/ml.
Plasma samples were tested diluted 1:20 in 0.1% BSA in PBS/
Tween. The cut-off value was determined as the mean of the
absorbance values recorded for negative samples, and samples
were considered positive if the ratio of the tested/mean negative
values was .2.1. A panel of HCV-negative sera from France and
Cambodia was used to provide negative controls.
The presence of anti-core+1/ARFP antibodies in plasma
samples negative for anti-core antibodies was confirmed using
ELISA test with synthetic core+1/ARFP peptide encompassing aa
sequence 91–106 of the protein, as previously described [4].
Cell transfection and luciferase assay
The Huh-7 cell line was kindly provided by R. Bartenschlager
and BHK-21 and HeLa cell lines by B. Roizman. All cell types
were initially purchased in ATCC Cell Biology Collections. Cells
were cultured in standard conditions, and transfected using JetPEI
transfection reagent (Polyplus). Luciferase activity was measured
with a Glomax 20/20 luminometer [16].
Western blot
Cells were solubilized using the Triple Detergent Reagent
supplemented with a protease inhibitor cocktail (Roche) and
0.07 mM PMSF and separated by 15% SDS-PAGE, transferred
onto nitrocellulose membranes (Protran). For western blotting
plasmas were used at a 1:200 dilution, followed by HRPO-labelled
anti-human IgG (Dako). Alternatively, rabbit antibodies to HCV
core [34] and core+1/ARFP, and HRPO-labelled anti-rabbit IgG
(Chemicon) were used.
Results
Patients with no detectable anti-core antibodies have a
strong anti-core+1/ARFP response
We analysed the prevalence of antibodies directed against HCV
core and core+1/ARF proteins in a group of patients from
Figure 2. The prevalence of anti-core antibodies in a panel of 58 HCV-positive plasma samples from Cambodia, detected by ELISA
based on core synthetic peptide aa(3–75). The panel included 28 plasma samples from individuals infected with HCV-6; 21 HCV-1b; 8 HCV-1a;
and 1 HCV-2a samples. Twenty-nine HCV-negative samples from individuals living in Cambodia were included in the panel as negative controls. Three
of 58 plasma samples (all from HCV-1a infected individuals, designated as p31, p32 and p34) were found negative for anti-core antibodies.
doi:10.1371/journal.pone.0015871.g002
Figure 3. Detection of anti-core and anti-core+1/ARFP anti-
bodies in plasma of HCV-1a genotype. Lack of anti-core antibodies
in p31, p32 and p34 plasma samples by ELISA based on core aa(1–120)
antigen correlated with strong anti-core+1/ARFP responses detected
using ELISA based on core+1/ARF aa(14–160) protein.
doi:10.1371/journal.pone.0015871.g003
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Table 1. Serological profiles in Cambodian patients infected with genotype 1a HCV.
Sample
Number Viral load
c-100
(NS4)
c-33
(NS3)
C22
(core) NS5
Anti-core
aa(1-120)
Anti-core+1/
ARFP
Core Ag
(fmol/L)
p29 8 065 471 0 4+ 4+ 4+ + - 6300
p30 342 966 4+ 4+ 3+ 0 + - 5200
p31 177 463 4+ 4+ 0 0 - +++ -
p32 384 746 4+ 4+ 0 0 - +++ 690
p34 4 895 775 4+ 4+ 0 0 - +++ 5800
p35 12 091 0 3+ 2+ 0 + - -
p36 85 589 0 4+ 4+ 0 + - -
p37 15 069 598 0 0+ 4+ 0 + - 7200
The absence of antibodies directed to epitopes localized in the immunodominant region of core aa(1–120) in plasma samples designated as p31, p32, p34 was
confirmed using Chiron RIBA HCV 3.0 Strip Immunoblot Assay (SIA) (Novartis Vaccines and Diagnostics, Inc., Emeryville, CA). Virus load in all these plasma samples of 1a
genotype was determined by b-DNA assay (Versant HCV RNA 3.0, Siemmens Health Care Diagnostics St. Denis, France) and the presence of HCV core protein was
determined by a commercial ELISA assay Ortho Diagnostics (Wako, Germany).
doi:10.1371/journal.pone.0015871.t001
Figure 4. Amino-acid sequence alignment of the core region derived from three HCV-1a isolates positive for anti-core antibodies
(p29, p30, p36) and those that were negative for anti-core antibodies (p31, p32, p34). cDNA fragments from the HCV core region were
obtained and cloned into the TOPO TA vector as described inMaterial andMethods. Three clones were sequenced for each patient and all three were identical
for each patient. Protein sequences were analyzed using the CLUSTAL W program. The amino-acid sequence of the HCV-1a H reference strain is shown.
doi:10.1371/journal.pone.0015871.g004
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Cambodia. The panel included 58 HCV-positive plasma samples
(28 positive for genotype 6 HCV, 21 for genotype 1b, 8 for
genotype 1a and 1 for genotype 2) and 29 plasma control samples,
also from Cambodia, negative for HCV antibodies when assessed
by routine ELISA and for HCV RNA by PCR. ELISA assays were
developed, using recombinant proteins and synthetic peptides
issued from HCV core and core+1/ARF proteins (Figure 1).
Most plasma samples from HCV-infected patients (55/58) were
positive for anti-core antibodies when tested using a synthetic core
peptide aa(3–75) (Figure 2). However, 3 patients (designated p31,
p32 and p34) infected with genotype 1a HCV showed negative for
anti-core antibodies. This observation was confirmed using HCV
core protein aa(1–120) (Figure 3).
The plasma samples from the panel were tested in parallel for
their reactivity with recombinant core+1/ARFP. Anti-core+1/
ARFP antibodies were detected in 8 serum samples; 5 of them
were from patients infected with genotype 6 HCV and 3 from
patients infected with genotype 1a HCV. Significantly, the highest
levels of anti-core+1/ARFP antibodies were detected in the 3
plasma samples from patients infected with HCV 1a and lacking
anti-core antibodies (Figure 3). The presence of anti-core+1/
ARFP antibodies in these plasma samples was confirmed using
ELISA test with synthetic core+1/ARFP peptide encompassing aa
sequence 91–106 of the protein (data not shown).
Further analyses carried out using the Chiron RIBA HCV 3.0
Strip Immunoblot Assay (SIA) confirmed the absence of antibodies
directed against the core protein (Table 1). This third generation
semi-quantitative RIBA assay measures antibodies directed to core
antigen c22p, synthetic peptide aa(10–53) and non structural
proteins: NS3 c33c recombinant protein aa(1192–1457), NS4
peptides c5-1-1 aa(1694–1735) and c100p aa(1920–1935) and NS5
recombinant protein (NS5r) aa(2054–2995). Proteins c33 and
NS5r are produced as fusion proteins with human superoxide
dismutase. The intensity of the coloured bands is proportional to
the amount of bound antibody and graded from 0 to 4+ [36,37].
Although no anti-NS5 antibodies could be detected for patients
p31, p32 and p34, all tested positive for NS4 and NS3 antibodies,
in addition to the strong anti-core+1/ARFP responses. Thus, the
lack of anti-core antibodies was not due to a general defect of the
humoral immune response in these patients.
Figure 5. Nucleotide sequence alignment of the cDNA corresponding to the HCV core protein region shown in Figure 4. Non-
synonymous mutations at nucleotides 223 and 317 are boxed; 10 synonymous mutations specific for the three core-antibody negative patients (p31,
p32, p34) were observed. Nucleotide sequences were analyzed using the CLUSTAL W program.
doi:10.1371/journal.pone.0015871.g005
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Different levels of HCV core antigen were detected in these
plasma samples. Patient p34 was strongly positive, p32 weakly
positive for HCV core antigen, whereas p31 was found negative.
These results correlated with the viral load, since p31 contained
the lowest levels of the virus, and core antigen assay is considered
less sensitive that detection of virus RNA by the b-DNA assay.
Analysis of the core region of HCV isolates derived from
the anti-core antibody negative patients
We investigated further whether the absence of anti-core
antibodies in the three patients described above was associated
with particular mutations in the core gene. The nucleotide and
amino-acid sequences of the core region derived from the three
anti-core negative patients (p31, p32, p34) as well as three anti-
core positive patients of genotype 1a (p29, p30, p36) were
analysed. HCV RNA was extracted from plasma, amplified, and
cloned into an expression vector. Three clones per sample were
sequenced. Amino-acid and nucleotide sequences were aligned
using the CLUSTAL W program. As shown in Figure 4 the core
ORF was intact and a high amino-acid sequence homology was
observed in all plasma samples analysed as compared with a
consensus genotype 1a HCV core sequence. No substitutions in
the aa (9–11) region were detected that could explain a more
efficient initiation of synthesis of core+1/ARFP from this site [19].
Two amino acid changes T.A at aa75 and S.N at aa106 were
found. However, similar substitutions have already been reported
that were not associated with the absence of anti-core antibodies
[38].
Nevertheless, several nucleotide mutations were found in the
core region of these patients as compared to a consensus sequence
issued from genotype 1a HCV or the Cambodian HCV1a patients
with normal core antibody levels (Figure 5). Two C.T and A.G
transition mutations, situated at nucleotides 223 and 317 give rise
to the amino acid changes cited directly above. Other mutations in
the core region are synonymous and most of them (7/10) are
positioned in the region encompassing aa(99–124). All synony-
mous mutations concern the third base, 5 represent a T.C
mutation, 3 a C.T, 1 G.A, and 1 A.G. Interestingly, all three
core antibody negative patients harboured identical mutations.
In the deduced core+1/ARFP amino-acid sequence (Figure 6),
several changes were found in p31, p32 and p34 samples and all of
these were situated in the region corresponding to aa(73–158).
The core region of the HCV isolates derived from the
anti-core antibody negative patients is functional in vitro
It was thus interesting to see whether in spite of numerous
mutations, the core region of HCV RNA could be expressed in
mammalian cells. The core-coding region from one of the anti-
core negative patients was cloned into a eukaryotic expression
vector (Figure 7A) and transiently expressed in mammalian cells:
BHK-21, Huh7 and HeLa. This resulted in the production of the
21kDa core protein that was recognised by anti-core MAbs
specific for the N-terminal part of core (Figure 7D). This protein
was also reactive with the three plasma found negative for anti-
core antibodies by ELISA and routine assays (p31, p34, p32) and
with plasma positive for anti-core antibodies (p36). These results
demonstrated that unusual anti-core antibodies might be present
in these three plasma samples, as they failed to recognise core
antigens derived from the immunodominant N-terminal part of
the protein. These antibodies were weak and detectable only by
Western Blot with full length core protein. These data suggest that
anti-core antibodies in these plasma samples were probably
Figure 6. Deduced core+1/ARFP amino-acid sequences from cDNA shown in Figure 5. The sequences relate to isolates positive for anti-
core antibodies (p29, p30, p36) and the three HCV-1a isolates negative for anti-core antibodies (p31, p32, p34). The corresponding amino-acid
sequence of the consensus genotype 1a HCV is also shown.
doi:10.1371/journal.pone.0015871.g006
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directed against the C-terminal part of the core protein,
downstream from aa120.
We also examined the expression of core+1/ARFP in vitro from
RNA of one of the three particular patients, using the luciferase
tagging approach [8], since untagged core+1/ARFP is very
unstable in transfected cells [5,7,20,21]. Transient expression of
core+1/ARFP-LUC was observed and the levels of transfection in
Huh7 cells (Figure 8B), but also in BHK-21 and HeLA cell lines
(not shown), was consistently (at least 2.5 fold) higher than that
from a prototype 1a HCV RNA.
These results provided evidence that the core gene of the anti-
core antibody negative patients is fully functional, as it efficiently
supports the synthesis of both HCV core and core+1/ARF proteins
in transfected cells. Furthermore, these observations demonstrated
an advantage when core+1/ARFP is expressed from this sequence
compared to that of the prototype HCV-1a. These observations
suggest that the expression of core+1/ARFP may also be favoured
from this mutated RNA during natural HCV infection.
Analyses of HCV RNA secondary structure
Synonymous mutations could affect the stability and secondary
structure of RNA. Especially an enrichment in cytosine bases at
synonymous sites might have an effect on RNA stability [39].
Therefore, differences in the structure of HCV RNA in the core-
coding region could play a role in the initiation of translation from
internal codons or in frame-shift events. Thus, prediction analyses
of the HCV RNA secondary structure were carried out using the
m-fold computational program. The entire core region was used to
predict the effect of mutations on the HCV RNA secondary
structure.
Strikingly, major differences were seen in SL248 when serum
samples with the unusual serological profile were considered,
compared with the prototype H strain of genotype 1a (Figure 9). In
particular, GC.AT changes at nucleotides 317 and 318 alter the
RNA structure by enlarging a bulge that brings AUG-85 from its
original position at a stem into the loop structure. Such changes
were not found in three RNA samples from the panel of HCV-1a
Figure 7. Expression of the HCV core protein from an anti-core negative patient (p34) in mammalian cells. (A) Schematic
representation of constructs used for the eukaryotic expression of core from the p34 HCV-1a isolate using plasmid pHPI8162 and HCV-1a H strain
using plasmid pHPI 8161 (described in Material and Methods). An artificial stop codon was inserted at the 39 end of the core gene (STOP).
(B) Transient expression of the cloned HCV core gene in cultured cells. Cells were transfected with pHPI 8161 or pHPI 8162 plasmids, or the pCI empty
vector. After 48 hours, cell lysates were analyzed by Western blotting using rabbit anti-core antibodies. Lane 1: cells transfected with pCI empty
vector; lane 2: with a plasmid encoding HCV core (H strain); lane 3: with a plasmid encoding HCV core p34. The 21 kDA HCV core protein was
detected in of all cell types. (C) The expressed core protein (M.wt. 21 KDa) is reactive with all three unusual plasma samples, p31 p32 and p34 and
with a control plasma p36 positive for anti-core antibodies in all assays. NP –HCV negative plasma; extract from cells transfected with pCI control
plasmid (Lane 1) and from cells transfected with a plasmid encoding HCV core p34 (Lane 2). (D) The expressed core protein is reactive with anti-core
MAbC7-50 that recognizes an epitope localized in the aa(21–57) sequence. Extract from cells transfected with the pCI control plasmid (Lane 1), with a
plasmid encoding HCV core from H strain (Lane 2) and with a plasmid encoding HCV core from p34 (Lane 3).
doi:10.1371/journal.pone.0015871.g007
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genotypes with normal serological profiles. Additional mutations
in SL337 might involve a G.A change at nucleotide 363, and
T.C at 372, reducing the size of the upper terminal loop.
Altogether, the prediction analysis of HCV RNA revealed
important conformational changes for patients with high anti-
core+1/ARFP antibody responses within the core-coding region
stem-loop structure that contains the core+1/ARFP initiator AUG-
85 codon. It is intriguing to speculate that these changes could
favour the initiation of core+1/ARFP synthesis in these patients.
Discussion
The HCV core gene is more conserved than is necessary to
conserve the encoded protein sequence [3], suggesting other
functions for the virus RNA. Indeed, a second protein encoded by
the core region of the genome has been discovered, designated
here as core+1/ARFP (for review, see [24,40]). The role of
core+1/ARFP in the virus cycle and in the pathogenesis of HCV
infection remains obscure, and this protein is not required either
for virus replication or for production of infectious HCVcc (JFH1)
in cell culture systems [16,23]. Nevertheless, several studies have
provided indirect evidence that core+1/ARFP is effectively
produced during the natural HCV infection [9,27].
In this study we have investigated the presence of anti-core and
anti-core+1/ARFP antibodies in plasma samples fromHCV-infected
individuals living in Cambodia. Anti-core+1/ARFP antibodies were
detected in 8/58 serum samples; 5 individuals were infected with
genotype 6 HCV and 3 with genotype 1a. Generally, the levels of
anti-core+1/ARFP antibodies (P/N values) were relatively low, and
in six such cases anti-core antibody responses were normal. However,
3 patients infected with genotype 1a HCV developed exceptionally
strong anti-core+1/ARFP responses and had no detectable antibod-
ies directed towards the N-terminus of core.
Analyses of the HCV RNA from these patients showed that the
entire core region was present and was functional, since the cloning
and expression of this RNA resulted in the production of full-length
core protein in mammalian cells. Also, the 59UTR of these isolates
was intact, excluding the possibility of abnormal expression of the
HCV polyprotein (Figure 10). Furthermore, analyses of the amino-
acid sequence of core protein predicted from its gene sequence did
not show any specific changes that could explain the unusual
serological profile. The deduced core+1/ARFP amino-acid se-
quence in the +1 frame was extremely conserved between the three
patients, but was considerably different from that of the prototype
1a HCV or from the sequence seen in other Cambodian patients
infected with genotype 1a HCV.
Figure 8. Expression of LUC-tagged core+1/ARFP construct from plasma p34 in Huh-7 cells. (A) Schematic representation of the Luc-
tagged constructs. Core+1/ARFP coding sequences were fused in frame with the firefly Luciferase gene, under the transcriptional control of the CMV
promoter and the translational control of the HCV-1a IRES. 1: core+1/ARFP from HCV-1a H strain (pHPI8234), 2: anti-sense core+1/ARFP construct from
HCV-1a H strain pHPI8235 (negative control, see arrow), 3: core+1/ARFP from patient p34 (pHPI8227).(B) Huh-7 cells were transfected with each
plasmid and the relative Luciferase activity derived from each construct were determined. The LUC levels were arbitrarily set at 100% for pHPI 8234.
Values plotted correspond to the mean obtained in three separate experiments carried out in duplicate. Error bars represent standard deviation.
Similar results were obtained using HeLa and BHK-21 cells.
doi:10.1371/journal.pone.0015871.g008
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Interestingly, the absence of ‘‘normal’’ anti-core antibodies in 3
patients correlated with several identical synonymous mutations in
the core gene. Most of these (7/10) were positioned in the region aa
(99–124), encoding the so called ‘‘short form’’ of core+1/ARFP [20].
There is increasing evidence that ‘‘silent’’ mutations that do not alter
the amino-acid composition of a gene product can affect transcrip-
tion, splicing, or mRNA transport. The synonymous mutations do
not alter mRNA levels, but they could influence RNA stability and
change the rate of protein synthesis and thus cause a protein to fold
into a alternative structure [41,42]. Thus, they would have
phenotypic effects with clinically important consequences [42].
Prediction analyses showed that the mutations in the core gene
induce conformational changes in the internal loop of SL248 and in
the apical loop of SL332 of HCV RNA, compared to HCV-1a RNA
from patients with a normal anti-core response. Since SL248 contains
codons 85–87 implicated in internal initiation of translation and
production of the core+1/ARFP [8], such conformational changes
could affect translation initiation within the core-coding region and
favour the synthesis of the core+1/ARFP. The analyses of clonedHCV
RNA also showed that although the nucleotide sequence spanning
codons 85–87 was not altered, nucleotide changes at position 317 (CC
to AT) resulted in a conformational change of the RNA structure that
shifts AUG-85 from a stem into an internal loop. Such a change may
favour the initiation of translation at position 85. Indeed, we detected
an increased level of core+1/ARFP-LUC expression in transiently
transfected mammalian cells when the sequence contained these
mutations (Figure 8).
Our findings suggest that the absence of detectable anti-core
antibodies, and the production of a strong anti-core+1/ARFP
response, can be related to specific nucleotide motifs or mutations
in the core and ARFP/core+1-coding region. Thus, in patients
harbouring RNA with such motifs/mutations, efficient internal
translation initiation at AUG-85 probably leads to the production
of higher levels of core+1/ARFP. Core+1/ARFP is considered to
be a short–lived and very labile protein [5], thus it can also be
hypothesized that core+1/ARFP bearing these alterations would
be of increased stability in the core-antibody negative patients.
It is noteworthy that, although core+1/ARFP is conserved
amongst different HCV genotypes, the length of core+1/ARFP
appears to be genotype-specific: by database analyses the longest
form of core+1/ARFP has been deduced to be that of the 1a
genotype [5]. In agreement with this, the three Cambodian
patients in question harboured genotype 1a HCV.
In our study, cDNA from these patients induced the synthesis of
the full-length 21 kDA core protein upon cloning and expression
in mammalian cells (Figure 4). In addition, different concentra-
tions of HCV core antigen could be detected in plasma samples
from each of the three patients. Thus, the HCV variants (p31, p32,
Figure 9. Prediction of stem-loop 248 and stem-loop 332 RNA folds, for HCV-1a H strain, the p36 isolate (positive for anti-core and
negative for anti-core+1/ARFP antibodies) and p34 (negative for anti-core and positive for anti-core+1/ARFP). RNA secondary
structure was predicted using the m fold program. Open boxes indicate structure alterations in the internal loop of stem-loop 248 and in the apical
loop of stem-loop 332. Open circles represent the locations of internal translation initiation codons (AUG 85 and 87) that serve for core+1/ARFP
synthesis. Gray circles represent the nucleotides that are altered in isolates from anti-core+1/ARFP antibody positive patients.
doi:10.1371/journal.pone.0015871.g009
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p34) identified in this study are not deficient in core protein
production, but the patients rather induce the unusual pattern of
the immune response. Indeed, the patients with distinctive (and
identical) mutations in the core gene sequence seem to produce
anti-core antibodies directed to the less immunogenic, C-terminal
part of the protein. The question remains as to the reason of
production of such unusual anti-core antibodies in the three
Cambodian patients. One possibility is that these patients could
produce increased levels of so-called ‘‘mini-cores’’, as shown in
studies in vitro [43]. Indeed, the synthesis of short forms of core (8–
14 kDa) that contain the C-terminal portion of the protein was
demonstrated for several infectious HCV strains that replicate in
vitro in hepatoma cell lines [43]. These ‘‘mini-cores’’ are
synthesized by internal translation initiation from initiator codons
in close proximity to AUG-85, the main initiation codon for
core+1/ARFP. Although they lack the RNA-binding region and
immunodominant core epitopes, the ‘‘mini-cores’’ seem to be
important functional components of the HCV protein repertoire,
as they might mediate some biological functions of core, such as
binding to lipid droplets [43]. The viruses that produce mini-cores
(genotypes 1 and 2) also express larger core proteins that could
play a role in particle formation [43]. The core assay involves
antibodies that recognise epitopes in both N-and C-terminal parts
of core. Thus it can potentially detect both the full-length and
mini-core proteins. It is tempting to speculate that « mini-core »
and core+1/ARFP may share common regulatory elements for
internal translation initiation and therefore there could be a link
between ‘‘mini-core’’ and core+1/ARFP production in vivo.
In conclusion, we provide further evidence for the synthesis of
core+1/ARFP protein during natural HCV infection. We also
demonstrate that unusually high levels of anti-ARFP antibodies
can be linked to a lack of normal anti-core antibody responses.
The synthesis of core+1/ARFP in such patients might be favoured
by synonymous mutations in the core coding sequence, situated
close to AUG-85, which induce conformational changes in SL248
and SL337. Thus higher levels of core+1/ARFP production may
be linked to the properties of the mutated HCV core. Since HCV
core protein is thought to play a major role in HCV pathogenesis,
it would be worthy to determine whether negative result in anti-
core antibody assay (and/or increased levels of anti-core+1/
ARFP) could identify patients harbouring mutated core sequences,
and whether this unusual serological pattern is associated with a
particular pathology during HCV infection.
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